Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,134
  • Shares Outstanding, K 55,044
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,800 K
  • 60-Month Beta 2.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.19
Trade ONCY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2500 +52.80%
on 01/10/22
2.0400 -6.37%
on 01/20/22
+0.4000 (+26.49%)
since 12/21/21
3-Month
1.2500 +52.80%
on 01/10/22
2.3100 -17.32%
on 10/22/21
-0.3900 (-16.96%)
since 10/21/21
52-Week
1.2500 +52.80%
on 01/10/22
4.8300 -60.46%
on 04/08/21
-0.8100 (-29.78%)
since 01/21/21

Most Recent Stories

More News
Double-Digit Growth in Global Cancer Immunotherapy Market to Drive Advancements Ahead of 2030

VANCOUVER – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at incredible rates. According to Precedence Research, the global cancer immunotherapy...

ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
EXAS : 74.03 (-2.63%)
SNY : 51.24 (-1.63%)
NVS : 87.03 (-1.32%)
BGNE : 251.45 (+0.03%)
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –January 20, 2021 – USA News Group  –  As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of...

AVRN : 0.0104 (-13.33%)
ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
INCY : 74.79 (+0.04%)
GILD : 68.51 (+1.03%)
ARVN : 67.09 (-0.36%)
PFE : 52.79 (-2.33%)
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer

Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to...

ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
LPTX : 2.11 (-11.72%)
GMDA : 3.24 (+9.46%)
ALXO : 15.44 (-3.92%)
MRK : 79.98 (-0.95%)
Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins    Company moving to full enrollment pending independent safety review    Multi-center trial...

ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – January 14, 2022 – USA News Group  –  Cancer cases are on the rise, according to a new study comparing the number of cancer...

ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
INCY : 74.79 (+0.04%)
PFE : 52.79 (-2.33%)
AZN : 59.10 (-1.78%)
RHHBY : 49.1200 (-0.57%)
New Treatments Needed as Breast Cancer Was Leading Killer of Female Cancer Patients in 2019

VANCOUVER – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer diagnoses globally in 2010 and 2019. Among the data, researchers witnessed that global...

ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
INCY : 74.79 (+0.04%)
PFE : 52.79 (-2.33%)
AZN : 59.10 (-1.78%)
RHHBY : 49.1200 (-0.57%)
Promising Developments in Breast Cancer Treatments Ahead in 2022

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – January 12, 2022 – USA News Group  –  So far in 2022, there have already been some impressive developments in the battle...

ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
ILMN : 365.94 (-3.81%)
ZLAB : 50.58 (-3.10%)
MRUS : 25.90 (-0.54%)
VERU : 4.90 (-5.95%)
Biotech Sector Answering Calls for New Breast Cancer Treatment Developments in 2022

VANCOUVER – USA News Group – So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female...

ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
ILMN : 365.94 (-3.81%)
ZLAB : 50.58 (-3.10%)
MRUS : 25.90 (-0.54%)
VERU : 4.90 (-5.95%)
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –January 10, 2021 – USA News Group  –  Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed...

ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
ABBV : 131.98 (-0.79%)
NVS : 87.03 (-1.32%)
NEO : 21.59 (-1.33%)
TMO : 580.33 (-1.33%)
Drug Developers Gaining Positive Results in Fight Against Blood Cancers

VANCOUVER – USA News Group – Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as leukemia, lymphoma and myeloma. According to analysts at Markets and Markets,...

ONCY : 1.9100 (-3.05%)
ONC.TO : 2.36 (-4.45%)
ABBV : 131.98 (-0.79%)
NVS : 87.03 (-1.32%)
NEO : 21.59 (-1.33%)
TMO : 580.33 (-1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 2.2133
2nd Resistance Point 2.1167
1st Resistance Point 2.0133
Last Price 1.9100
1st Support Level 1.8133
2nd Support Level 1.7167
3rd Support Level 1.6133

See More

52-Week High 4.8300
Fibonacci 61.8% 3.4624
Fibonacci 50% 3.0400
Fibonacci 38.2% 2.6176
Last Price 1.9100
52-Week Low 1.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar